WO2003066557A1 - Synthesis of imperanene derivatives from hydroxymatairesinol - Google Patents

Synthesis of imperanene derivatives from hydroxymatairesinol Download PDF

Info

Publication number
WO2003066557A1
WO2003066557A1 PCT/FI2003/000042 FI0300042W WO03066557A1 WO 2003066557 A1 WO2003066557 A1 WO 2003066557A1 FI 0300042 W FI0300042 W FI 0300042W WO 03066557 A1 WO03066557 A1 WO 03066557A1
Authority
WO
WIPO (PCT)
Prior art keywords
imperanene
iii
hydroxymatairesinol
ester
acid
Prior art date
Application number
PCT/FI2003/000042
Other languages
French (fr)
Inventor
Rainer SJÖHOLM
Patrik Eklund
Annika Riska
Original Assignee
Hormos Medical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hormos Medical Corporation filed Critical Hormos Medical Corporation
Priority to AU2003201438A priority Critical patent/AU2003201438A1/en
Publication of WO2003066557A1 publication Critical patent/WO2003066557A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers

Definitions

  • This invention relates to a method for the synthesis of imperanene from hydroxymatairesinol.
  • the invention concerns also a group of new intermediates.
  • Imperanene a phenolic compound belonging to the rare class C 6 -C 4 -C6 of natural products, has been isolated from rhizomes of the plant Imperata cylindrica (1). Like some other compounds of the C 6 -C 4 -C 6 class (2, 3, 4), imperanene has been shown to have biological activity, including antiplatelet aggregation. The search of new platelet aggregation inhibitors for the treatment of diseases such as heart attack and stroke is an active research area, in which imperanene is a potential chemoterapeutic agent.
  • hydroxymatairesinol can be produced by extracting finely divided wood material, preferably spruce knotwood, with a polar solvent or solvent mixture and precipitating hydroxymatairesinol from the extract as a complex.
  • Suitable solvents to be used in the extraction step are, for example, pure ethanol or a mixture of ethanol and ethyl acetate.
  • a complexing agent which preferable is a carboxylate, such as acetate, of an alkali metal, such as potassium, an earth alkali metal, or ammonium.
  • carboxylates form crystallisable adducts with hydroxymatairesinol.
  • An especially preferable complexing agent is potassium acetate, which gives an easily crystallisable potassium acetate adduct of hydroxymatairesinol. This adduct is also rich in the (-) hydroxymatairesinol diastereomer.
  • An object of this invention is a method for the synthesis of imperanene from a source available in large quantities, namely hydroxymatairesinol, especially hydroxymatairesinol derived from wood.
  • this invention concerns a method for the preparation of imperanene (IV) from hydroxymatairesinol (I), wherein hydroxymatairesinol (I)
  • the method is characterized in that either i) the acid (II) is esterified by use of an alcohol R-OH, wherein R is an alkyl or aryl group, to give an ester of formula (III)
  • R is an alkyl or aryl group, followed by reducing the ester (III) to imperanene
  • the invention concerns the use of an ester of the formula (III)
  • R is an alkyl or aryl group, as an intermediate in the synthesis of imperanene.
  • the invention concerns a novel ester of the formula (III)
  • R is an alkyl or aryl group, provided that R is not methyl.
  • Hydroxymatairesinol appears as two diastereomers, namely (-) hydroxymatairesinol and (-) allo-hydroxymatairesinol. The word
  • hydroxymatairesino shall in the definition of this invention be understood to cover any pure geometric isomer or pure stereoisomer or any pure diastereomer or mixture of isomers or diasteromers of the compound. Salts, adducts and complexes of the compound shall also be understood to be covered by the term. Also, wood extracts in which hydroxymatairesinol is the major component are understood to be covered by the term.
  • the acid (II) can be directly reduced to imperanene (IV), for example by use of lithium aluminium hydride, it is preferable to first esterify the acid (II) and then reduce the ester (III) to imperanene (IV).
  • the alcohol used for the esterification of the acid (II) can be any aliphatic or aromatic alcohol, alcohols having R substituents containing up to 20 carbon atoms may be preferred. Particularly preferred are the alcohols R- OH, wherein R is an alkyl or aryl group containing 1 to 12 carbon atoms. Most preferred are alcohols where R is an alkyl group containing 1-3 carbon atoms.
  • the esterification is preferably performed as an acid catalysed esterification using the alcohol as solvent or by heating a mixture of (II) and the alcohol under removal of the released water.
  • ester (III) or alternatively, the acid (II), is preferably reduced to imperanene either by catalytic hydrogenation or by a chemical reduction.
  • the catalytic hydrogenation is preferably carried out at high pressures and elevated temperatures.
  • a suitable catalyst is a metal or metal oxide or a mixture of metals and/or metal oxides.
  • a suitable catalyst can be mentioned copper/chromium oxide catalyst.
  • the chemical reduction is carried out, for example, by use of sodium metal and alcohol. More preferably, the reduction is carried out by use of a metal hydride such as lithium aluminium hydride, or lithium or sodium borhydride
  • the final product, imperanene (IV), can be obtained as a mixture of the two enantiomers.
  • esters of formula (III) are new except for the methyl ester, which has been prepared in order to establish the structure of the acid (II) (reference 6). However, the esters (III) have not earlier been suggested for use as intermediates in the synthesis of imperanene.
  • the hydroxymatairesinol diasteromers can be used for the synthesis according to this invention, it may be desirable to use the (-) hydroxymatairesinol diastereomer, which is available in large quantities after the extraction process.
  • the hydroxymatairesinol is in the form of a complex or adduct, precipitated from an extract obtained by extracting wood material with a polar solvent, such as a potassium carboxylate adduct of hydroxymatairesinol.
  • the hydroxymatairesinol or its adduct in the starting material to be used in the synthesis does not necessarily need to be purified from other components.
  • Example 2 0.554 g of the methyl ester prepared in Example 2 (1.5 mmol, purity 96 %) was dissolved in 40 ml dry THF and LAH (0.367 g, 9.7 mmol) was portionwise added. The mixture was stirred at room temperature under an atmosphere of argon (flame-dried glassware) for 3.5 h. The reaction was then quenched by adding the reaction mixture to 100 ml distilled water. The pH value was adjusted to 6 with 10 % HC1 and the mixture was extracted with dichloromethane (3 x 50 ml). The organic phase was washed with 50 ml saturated NaCl solution, dried over Na 2 S0 4 , and the solvent was removed under reduced pressure.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

This invention concerns a method for the preparation of imperanene from hydroxymatairesinol. In a first step hydroxymatairesinol is converted to 4-(4-hydroxy-3-methoxyphenyl)-2-(4-hydroxy-3-methoxyphenylmethyl)-but-3-enoic acid. This acid is then preferably esterified by use of an alcohol R-OH, wherein R is an alkyl or aryl group, to an ester (III), which is reduced to imperanene.The invention concerns also the use of esters (III) as intermediates in the synthesis of imperanene and novel esters of formula (III).

Description

SYNTHESIS OF IMPERANENE DERIVATIVES FROM HYDROXYMATAIRESINOL
FIELD OF THE INVENTION
This invention relates to a method for the synthesis of imperanene from hydroxymatairesinol. The invention concerns also a group of new intermediates.
BACKGROUND OF THE INVENTION
The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference.
Imperanene, a phenolic compound belonging to the rare class C6-C4-C6 of natural products, has been isolated from rhizomes of the plant Imperata cylindrica (1). Like some other compounds of the C6-C4-C6 class (2, 3, 4), imperanene has been shown to have biological activity, including antiplatelet aggregation. The search of new platelet aggregation inhibitors for the treatment of diseases such as heart attack and stroke is an active research area, in which imperanene is a potential chemoterapeutic agent.
Recently, the stereoselective synthesis of both enantiomers of imperanene was published (5). The single enantiomer isolated from Imperata cylindrica was thereby shown to be the (ιS)-enantiomer by comparison of optical rotation data (5). Ekman et al. isolated in 1979 the compound (E)-4-(4-hydroxy-3- methoxyphenyl)-2-(4-hydroxy-3-methoxyphenylmethyl)but-3-enoic acid from an acidified alkaline hydrolysate of Norway spruce (Picea abies) root extractives. They proved that this acid was formed by the degradation of hydroxymatairesinol, the most abundant lignan in Norway spruce (6). Hydroxymatairesinol is found in high concentrations, especially in knots and in the heartwood of branches in Norway spruce (7, 8). Unlike other lignans, hydroxymatairesinol can be isolated in large quantities from wood pulping processes.
It has recently been found that high amounts of hydroxymatairesinol can be produced by extracting finely divided wood material, preferably spruce knotwood, with a polar solvent or solvent mixture and precipitating hydroxymatairesinol from the extract as a complex. Suitable solvents to be used in the extraction step are, for example, pure ethanol or a mixture of ethanol and ethyl acetate. After the extraction step at least part of the solvent is preferably withdrawn before the addition of a complexing agent, which preferable is a carboxylate, such as acetate, of an alkali metal, such as potassium, an earth alkali metal, or ammonium. Such carboxylates form crystallisable adducts with hydroxymatairesinol. An especially preferable complexing agent is potassium acetate, which gives an easily crystallisable potassium acetate adduct of hydroxymatairesinol. This adduct is also rich in the (-) hydroxymatairesinol diastereomer.
SUMMARY OF THE INVENTION
An object of this invention is a method for the synthesis of imperanene from a source available in large quantities, namely hydroxymatairesinol, especially hydroxymatairesinol derived from wood. Thus, this invention concerns a method for the preparation of imperanene (IV) from hydroxymatairesinol (I), wherein hydroxymatairesinol (I)
Figure imgf000004_0001
(I)
in a first step is converted to the acid of formula (II)
Figure imgf000004_0002
The method is characterized in that either i) the acid (II) is esterified by use of an alcohol R-OH, wherein R is an alkyl or aryl group, to give an ester of formula (III)
Figure imgf000004_0003
wherein R is an alkyl or aryl group, followed by reducing the ester (III) to imperanene
Figure imgf000005_0001
(IV)
or
ii) the acid (II) is directly reduced to imperanene.
According to another aspect, the invention concerns the use of an ester of the formula (III)
Figure imgf000005_0002
(III)
where R is an alkyl or aryl group, as an intermediate in the synthesis of imperanene.
According to a third aspect, the invention concerns a novel ester of the formula (III)
Figure imgf000006_0001
(III)
where R is an alkyl or aryl group, provided that R is not methyl.
DETAILED DESCRIPTION OF THE INVENTION
Hydroxymatairesinol appears as two diastereomers, namely (-) hydroxymatairesinol and (-) allo-hydroxymatairesinol. The word
"hydroxymatairesino , shall in the definition of this invention be understood to cover any pure geometric isomer or pure stereoisomer or any pure diastereomer or mixture of isomers or diasteromers of the compound. Salts, adducts and complexes of the compound shall also be understood to be covered by the term. Also, wood extracts in which hydroxymatairesinol is the major component are understood to be covered by the term.
Although the acid (II) can be directly reduced to imperanene (IV), for example by use of lithium aluminium hydride, it is preferable to first esterify the acid (II) and then reduce the ester (III) to imperanene (IV).
Although the alcohol used for the esterification of the acid (II) can be any aliphatic or aromatic alcohol, alcohols having R substituents containing up to 20 carbon atoms may be preferred. Particularly preferred are the alcohols R- OH, wherein R is an alkyl or aryl group containing 1 to 12 carbon atoms. Most preferred are alcohols where R is an alkyl group containing 1-3 carbon atoms.
The esterification is preferably performed as an acid catalysed esterification using the alcohol as solvent or by heating a mixture of (II) and the alcohol under removal of the released water.
The ester (III) or alternatively, the acid (II), is preferably reduced to imperanene either by catalytic hydrogenation or by a chemical reduction.
The catalytic hydrogenation is preferably carried out at high pressures and elevated temperatures. A suitable catalyst is a metal or metal oxide or a mixture of metals and/or metal oxides. As example of a suitable catalyst can be mentioned copper/chromium oxide catalyst.
The chemical reduction is carried out, for example, by use of sodium metal and alcohol. More preferably, the reduction is carried out by use of a metal hydride such as lithium aluminium hydride, or lithium or sodium borhydride
The final product, imperanene (IV), can be obtained as a mixture of the two enantiomers.
The esters of formula (III) are new except for the methyl ester, which has been prepared in order to establish the structure of the acid (II) (reference 6). However, the esters (III) have not earlier been suggested for use as intermediates in the synthesis of imperanene.
Although both of the hydroxymatairesinol diasteromers can be used for the synthesis according to this invention, it may be desirable to use the (-) hydroxymatairesinol diastereomer, which is available in large quantities after the extraction process. According to one preferable embodiment, the hydroxymatairesinol is in the form of a complex or adduct, precipitated from an extract obtained by extracting wood material with a polar solvent, such as a potassium carboxylate adduct of hydroxymatairesinol.
The hydroxymatairesinol or its adduct in the starting material to be used in the synthesis does not necessarily need to be purified from other components.
The invention will be illuminated by the following non-restrictive Experimental Section.
EXPERIMENTAL SECTION
All commercially available chemicals were used as supplied by the manufactures. Hydroxymatairesinol was isolated from Norway spruce as described in the International patent Publication WO 00/59946. GC analyses were performed on a HP-5890 standard gas chromatograph equipped with a HP-5 column and a FID detector. The samples were silylated using hexamethyldisilazane-chlorotrimethylsilane in pyridine, prior to analyses. HRMS were recorded on a ZabSpecETOF system.
1H and 13C spectra were recorded on a JEOL JNM-A500 spectrometer at 500 and 125 MHz, respectively. 2D experiments were recorded using JEOL standard pulse sequences and chemical shifts are reported downfield from tetramethylsilane, numbering according to imperanene. The assignments of the H and 13C signals were based on homonuclear and heteronuclear direct and long-range correlation spectroscopy (COSY, HMQC, HMBC, COLOC). Preparative chromatography was performed on a BUCHI B-688 MPLC apparatus, using normal phase silica (Silica gel 40, > 400 mesh, 600 m2/g, Fluka). Analytical TLC was carried out on pre-coated aluminium based sheets (Merk 60 F254). Chiral LC-MS was performed on a PE-Sciex API 3000 instrument equipped with a CHIRALCEL OD-R analytical column (0.46 x 25 cm) using multiple reaction monitoring techniques (MRM).
Example 1
(E)-4-(4-hy droxy-3-methoxyphenyl)-2-(4-hydroxy-3- methoxyphenylmethyl) but -3-enoic acid (Compound II in Scheme 1)
Aqueous NaOH (0.6 M, 200 ml) was heated to 50 °C and hydroxymatairesinol (1.530 g, 4.1 mmol) was added. The temperature was adjusted 80 °C and the solution was stirred for 2.5 h, cooled to room temp and acidified with HCl-solution (6M) to pH ~1. The mixture was then extracted with dichloromethane (4 x 50 ml) and the organic phase was dried over Na2S0 . Evaporation of the solvent, using a rotary evaporator, left a light yellow solid (1.386g , 98 %) of Compound II in a purity of 94 %. Crystallisation from dichloromethane :diethylether (3:1) gave Compound II as white needles (1.068 g, 80 %) in a purity of 98 %. Mp. 126-128 °C.
HRMS m/z calculated for C19H20O6 (M+) 344.1260 found 344.1264. XH NMR (500 MHz, CDC13) δ 2.86 (IH, dd, J= 13.8, 6.9 Hz, H-7'b), 3.11 (IH, dd J= 13.7, 7.8 Hz, H-7'a), 3.41 (IH, dddd, J= 8.7, 7.9, 7.0, 0.9, H-8'), 3.78 (3H, s, H-OMe'), 3.88 (3H, s, H-OMe), 6.08 (IH, dd, J= 15.8, 8.8 Hz, H-8), 6.36 (IH, d, J= 15.4 Hz, H-7), 6.69 (IH, dd, J= 7.9, 2.0 Hz, H-6'), 6.72 (IH, d, J= 1.9 Hz, H-2'), 6.79 (IH, d, J= 7.9 Hz, H-5'), 6.81- 6.88 (3 H, complex, H-2, H-5, H-6). 13C NMR (500 MHz, CDC13) δ 38.74 (C-7'), 51.59 (C-8'), 55.87 (OMe'), 55.97 (OMe), 108.58 (C-2), 112.12 (C-2'), 114.50 (C-5'), 114.67 (C-5), 120.16 (C-6), 121.87 (C-6'), 124.45 (C-8), 129.36 (C-l), 130.52 (C-l '), 132.71 (C-7), 144.44 (C-4'), 145.84 (C-4), 146.61 (C-3'), 146.96 (C-3), 176.92 (C-9'). El m/z (relative intensity) 344 (13), 298 (5), 207 (5), 161 (7), 150 (12), 137 (100), 122 (2), 71 (6).
Example 2
(E)-4-(4-hydroxy-3-methoxyphenyl)-2-(4-hydroxy-3- methoxyphenylmethyl) but -3-enoic acid methylester (a compound of formula III in Scheme 1).
0.554 g of the acid II prepared in Example 1 (purity 98 %, 1.6 mmol) was dissolved in 55 ml methanol and 0.1 ml of 4:1 methanol-concentrated H2S0 (0.36 mmol) was added. The solution was stirred for 17 h at 50 °C and then poured into 70 ml saturated NaCl solution. The mixture was extracted with dichloromethane and the organic phase dried over Na2S04. Evaporation of the solvent gave 0.569 g (99 %) of the methyl ester in a purity of 92 %.
Crystallisation from dichloromethane-ether (1:1) gave 0.40 g (70 %) of the methyl ester as a yellow solid. Mp. 143-144 °C.
HRMS m/z calculated for C20H22O6 (M+) 358.1416 found 358.1422. *H NMR (500 MHz, CDC13) δ 2.85 (IH, dd, J= 13.7, 6.9 Hz, H-7'b), 3.08 (IH, dd J= 13.7, 8.1 Hz, H-7'a), 3.40 (IH, m, H-8'), 3.65 (3 H, s, 9'-
OMe),3.81(3H, s, H-OMe'), 3.88 (3H, s, H-OMe), 6.06 (IH, dd, J= 15.8, 8.8
Hz, H-8), 6.32 (IH, d, J= 15.9 Hz, H-7), 6.66-6.69 (2 H, complex, H-6', H-
2') 6.81 (IH, d, J= 8.5 Hz, H-5'), 6.80-6.86 (3H, m, H-2, H-5, H-6). 13C NMR (500 MHz, CDC13) δ 38.92 (C-7'), 51.74 (C-8'), 51.88 (9'- OMe ),
55.88 (OMe), 55.93 (OMe'), 108.22 (C-2), 111.75 (C-2'), 114.29 (C-5'),
114.44 (C-5), 120.18 (C-6), 121.80 (C-6'), 124.59 (C-8), 129.34 (C-l),
130.56 (C-l '), 132.47 (C-7), 144.23 (C-4'), 145.59 (C-4), 146.32 (C-3'),
146.65 (C-3), 174.19 (C-9'). El m/z (relative intensity) 358 (17), 299 (3), 222 (16), 190 (7), 175 (2), 161 (25), 137 (100), 122 (6). Example 3
Imperanene (Compound IV in Scheme 1)
0.554 g of the methyl ester prepared in Example 2 (1.5 mmol, purity 96 %) was dissolved in 40 ml dry THF and LAH (0.367 g, 9.7 mmol) was portionwise added. The mixture was stirred at room temperature under an atmosphere of argon (flame-dried glassware) for 3.5 h. The reaction was then quenched by adding the reaction mixture to 100 ml distilled water. The pH value was adjusted to 6 with 10 % HC1 and the mixture was extracted with dichloromethane (3 x 50 ml). The organic phase was washed with 50 ml saturated NaCl solution, dried over Na2S04, and the solvent was removed under reduced pressure. The residue was dried under vacuum, yielding 0.424 g (83 %) of imperanene as a white powder. Purity 94 %. The product was further purified by MPLC (ethylacetate:petroleum ether, 1 : 1) to yield 0.266 g (54 %) of imperanene in a purity > 98 %.
HRMS m/z calculated for C19H2205 (M+) 330.1467 found 330.1470. H NMR (500 MHz, CDC13) δ 2.62 (IH, m, H-8'), 2.68 (IH, dd, J= 13.4, 7.0 Hz, H-7'a) 2.74 (lH,dd, J= 13.4, 7.2 Hz, H-7'b), 3.56 (IH, dd, J= 10.7, 7.2 Hz, H-9'a), 3.66 (IH, dd, J= 10.6, 4.7 Hz, H-9'b), 3.81 (3H, s, OMe'), 3.88 (3H, s, OMe), 5.54 (IH, s, OH'), 5.68 (IH, s, OH), 5.92 (IH, dd, J= 16.0, 8.3 Hz, H-8), 6.34 (IH, dd, J= 15.9, 0.8 Hz, H-7), 6.66 (IH, dd, J= 8.2, 2.0 Hz, H-6'), 6.68 (IH, complex, H-2'), 6.81 (IH, d, J= 8.2 Hz, H-5'), 6.80-6.85 (3H, complex, H-6, H-5, H-2). 13C NMR (500 MHz, CDC13) δ 37.67 (C-7'), 47.60 (C-8'), 55.88 (C-OMe'), 55.91 (C-OMe), 65.25 (C-9'), 108.26 (C-2), 111.81 (C-2'), 114.21 (C-5'), 114.47 (C-5), 119.74 (C-6), 121.87 (C-6'), 128.42 (C-8), 129.75 (C-l), 131.54 (C-l '), 132.14 (C-7), 143.93 (C-4'), 145.33 (C-4), 146.34 (C-3'), 146.63 (C-3). El m/z (relative intensity) 330 (41), 312 (14), 219 (21), 193 (49), 175 (58), 151 (54), 143 (17), 137 (100).
It will be appreciated that the methods of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent for the expert skilled in the field that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are illustrative and should not be construed as restrictive.
References
1. Kimihiro Matsunaga; Masaoki Shibuya; Yasushi Ohizumi. J. Nat. Prod. 1995, 58, 138.
2. Dalia Green; Yoel Kashman; Ahron Miroz. J. Nat. Prod. 1993, 56, 1201.
3. Masayoshi Ishida; Takashi Hamasaki; Yuichi Hatsuda. Agr. Biol. Chem. 1979, 39, 2181.
4. Nada K. Gulavita; Shirley A. Pomponi; Amy E. Wright; Michelle Garay; Matthew A. Sills. J. Nat. Prod. 1995, 58, 954.
5. James C. Shattuck; Cheney M. Shreve; Organic Letters. 2001, 3, 3021.
6. Rainer Ekman; Risto T. Sjόholm; Rainer Sjoholm, Finn. Chem. Lett., 1979, 126.
7. Stefan Willfδr; Jarl Hemming; Markku Reunanen; Christer Eckerman; Bjarne Holmbom. Hydrophilic and lipophilic extractives in Norway spruce knots. Proc. 11th Inter. Symp. Wood Pulping Chem., ATIP, Nice, 2001.
8. Rainer Ekman. Acta Acad. Abo. Ser. B. 1979,39:3, 1. Scheme 1
Figure imgf000014_0001
111
Figure imgf000014_0002
IV

Claims

1. A method for the preparation of imperanene (IV) from hydroxymatairesinol (I), wherein hydroxymatairesinol (I)
Figure imgf000015_0001
(I)
in a first step is converted to the acid of formula (II)
Figure imgf000015_0002
(II)
characterized in that either i) the acid (II) is esterified by use of an alcohol R-OH, wherein R is a an alkyl or aryl group, to give an ester of formula (III)
Figure imgf000016_0001
(III) wherein R is as defined above, followed by reducing the ester (III) to imperanene
Figure imgf000016_0002
(IV) or
ii) the acid (II) is directly reduced to imperanene (IV).
2. The method according to claim 1, characterized in that reaction alternative i) is followed.
3. The method according to claim 2, characterized in that the ester (III) is reduced to imperanene (IV) by catalytic hydrogenation.
4. The method according to claim 2, characterized in that the ester (III) is reduced to imperanene (IV) by a chemical reduction.
5. The method according to claim 4, characterized in that the chemical reduction is performed by lithium aluminium hydride.
6. The method according to any of the foregoing claims, characterized in that R in the alcohol contains 1 to 20 carbon atoms.
7. The method according to claim 6, characterized in that R contains 1 to 12 carbon atoms.
8. An ester of the formula (III)
Figure imgf000017_0001
(III)
characterized in that R is an alkyl or aryl group, provided that R is not methyl.
9. The ester according to claim 8, characterized in that R contains 2 to 20 carbon atoms.
10. The ester according to claim 9, characterized in that R contains 2 to 12 carbon atoms.
11. The use of an ester of the formula (III)
Figure imgf000018_0001
(III)
where R is an alkyl or aryl group, in as intermediate in the synthesis of imperanene.
12. The use according to claim 11, wherein R contains 1-20 carbon atoms.
13. The use according to claim 12, wherein R contains 1-12 carbon atoms.
PCT/FI2003/000042 2002-02-05 2003-01-21 Synthesis of imperanene derivatives from hydroxymatairesinol WO2003066557A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003201438A AU2003201438A1 (en) 2002-02-05 2003-01-21 Synthesis of imperanene derivatives from hydroxymatairesinol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20020223A FI20020223A0 (en) 2002-02-05 2002-02-05 A process for preparing a biologically active compound and a group of novel intermediates
FI20020223 2002-02-05

Publications (1)

Publication Number Publication Date
WO2003066557A1 true WO2003066557A1 (en) 2003-08-14

Family

ID=8563065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2003/000042 WO2003066557A1 (en) 2002-02-05 2003-01-21 Synthesis of imperanene derivatives from hydroxymatairesinol

Country Status (3)

Country Link
AU (1) AU2003201438A1 (en)
FI (1) FI20020223A0 (en)
WO (1) WO2003066557A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1358203A (en) * 1972-01-07 1974-07-03 Beecham Group Ltd Derivatives of diphenyl alkanols
WO1997014670A1 (en) * 1995-10-18 1997-04-24 Kanoldt Arzneimittel Gmbh Lignans, a process for their production and pharmaceutical compositions and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1358203A (en) * 1972-01-07 1974-07-03 Beecham Group Ltd Derivatives of diphenyl alkanols
WO1997014670A1 (en) * 1995-10-18 1997-04-24 Kanoldt Arzneimittel Gmbh Lignans, a process for their production and pharmaceutical compositions and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DOYLE MICHAEL P. ET AL.: "Total synthesis of (S)-(+)-imperanene. Effective use of regio- and enantioselective intramolecular carbon-hydrogen insertion reactions catalyzed by chiral dirhodium(II) carboxamidates", J. ORG. CHEM., vol. 67, 2002, pages 2954 - 2959, XP002964958 *
EKLUND PATRIK C. ET AL.: "Synthesis of R-(-)-imperanene from the natural lignan hydroxymatairesinol", J. ORG. CHEM., vol. 67, 2002, pages 7544 - 7546, XP002964955 *
EKMAN RAINER ET AL.: "A degraded lignan from alkaline hydrolysis of Norway spruce root extractives", FINN. CHEM. LETT., 1979, pages 126 - 128, XP002964956 *
SHATTUCK JAMES C. ET AL.: "Enantioselective synthesis of imperanene, a platelet aggregation inhibitor", ORGANIC LETTERS, vol. 3, no. 19, 2001, pages 3021 - 3023, XP002964957 *

Also Published As

Publication number Publication date
AU2003201438A1 (en) 2003-09-02
FI20020223A0 (en) 2002-02-05

Similar Documents

Publication Publication Date Title
SU1128829A3 (en) Method of obtaining optically active norpinene compounds
EP2059493B1 (en) Recovery of phenol ligands during the production of isopulegol
Acharyya et al. Asymmetric total synthesis of naturally occurring spirocyclic tetranorsesquiterpenoid lanceolactone A
KR840002170B1 (en) Process for preparing substituted pyranone inhibitors of cholesterol synthesis
Hodgetts et al. Conjugate addition to 3-arylsulfinylchromones as a synthetic route to homochiral 2-substituted chromanones: scope and limitations
Kumari et al. Tandem IBX‐Promoted Primary Alcohol Oxidation/Opening of Intermediate β, γ‐Diolcarbonate Aldehydes to (E)‐γ‐Hydroxy‐α, β‐enals
Popsavin et al. Enantiodivergent synthesis of cytotoxic styryl lactones from d-xylose. The first total synthesis of (+)-and (−)-crassalactone C
Bekish et al. Transformation of esters into allyl halides via substituted cyclopropanols. Application in the synthesis of (2S, 3R, 7R/S)-3, 7-dimethyltridec-2-yl acetate and propionate, sex attractants of pine sawfly Diprion pini
Seto et al. Preparation of (±)-2-(2, 3-2H2) jasmonic acid and its methyl ester, methyl (±)-2-(2, 3-2H2) jasmonate
EP0442816A1 (en) Alpha-hydroxylic acids, process for preparing them and use
Hanselmann et al. Enantioselective Synthesis of a Wieland-Miescher Ketone Bearing an Angular Hydroxymethyl Group
WO2003066557A1 (en) Synthesis of imperanene derivatives from hydroxymatairesinol
Martinková et al. A stereoselective total synthesis of the HCl salts of mycestericins F, G and ent-F
Katritzky et al. Additions of 1-(. alpha.-alkoxybenzyl) benzotriazoles to enol ethers. New routes to 1, 3-diethers
Pedroso et al. Absolute configuration of clemateol
EP0306649A1 (en) 3,5-Dihydroxycarboxylic acids and their derivatives, processes for their preparation, their use as medicaments, pharmaceutic preparations and intermediate products
Giles et al. The asymmetric synthesis of 2-benzopyrans and their quinones through intramolecular diastereoselective ring-closure of titanium phenolates of phenolic aldehydes
Johnson et al. The chemistry of hindered systems. II. The acyloin reaction-an approach to regiospecifically hydroxylated tetramethylazacycloheptane systems
EP0685473B1 (en) Benzoheterocyclic compounds, as antioxidants
US4547586A (en) Preparation of 2-isopropenyl-or 2-isopropylidenyl-3-hexenoates from chrysanthemic acid esters
Rague et al. Halogenated enolates. Synthesis of 2-deoxypentose derivatives from D-glyceraldehyde
SU1225843A1 (en) Method of producing derivatives of 1,3-diazaadamantan-6-on
Lamb et al. Oxidation of the 8'-position of a biologically active abscisic acid analogue
JP7129394B2 (en) Process for producing 2-(1,2,2-trimethyl-3-cyclopentenyl)-2-oxoethyl carboxylate compound and hydroxymethyl 1,2,2-trimethyl-3-cyclopentenyl ketone, and halomethyl ( 1,2,2-trimethyl-3-cyclopentenyl)=ketone compound
Oritani et al. Syntheses of pentadienoic acids structurally related to abscisic acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP